Celcuity Inc
CELC
Company Profile
Business description
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Contact
16305 36th Avenue North
Suite 100
MinneapolisMN55446
USAT: +1 763 392-0767
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
87
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,772.00 | 1.00 | -0.01% |
CAC 40 | 7,636.10 | 29.81 | -0.39% |
DAX 40 | 23,853.07 | 56.54 | -0.24% |
Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
FTSE 100 | 8,754.13 | 6.83 | -0.08% |
HKSE | 24,072.28 | 211.87 | -0.87% |
NASDAQ | 20,369.73 | 96.27 | 0.47% |
Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
S&P 500 | 6,204.95 | 31.88 | 0.52% |
S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
SSE Composite Index | 3,444.43 | 20.20 | 0.59% |